Search

Your search keyword '"A Hartkopf"' showing total 3,590 results

Search Constraints

Start Over You searched for: Author "A Hartkopf" Remove constraint Author: "A Hartkopf"
3,590 results on '"A Hartkopf"'

Search Results

52. Speckle Interferometry at the U.S. Naval Observatory. XXIII

53. Speckle interferometry at SOAR in 2016 and 2017

54. Distances of Dwarf Carbon Stars

55. Speckle Interferometry of Red Dwarf Stars

57. Impact of maternal emotional state during pregnancy on fetal heart rate variability

58. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry

59. The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

62. Speckle Interferometry at the U.S. Naval Observatory. XXII

63. Binary Star Orbits. V. The Nearby White Dwarf - Red Dwarf pair 40 Eri BC

64. Update Mammakarzinom 2024 Teil 1 – Expertenmeinungen zu Brustkrebs in fortgeschrittenen Krankheitsstadien.

65. Breast Cancer and Mental Health: Incidence and Influencing Factors—A Claims Data Analysis from Germany.

66. Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer.

68. Trastuzumab treatment of patients with early, HER2-positive breast cancer in 17 certified German breast cancer centers

71. RECONSTRUCTING KUNGURIAN (CISURALIAN, PERMIAN) TERRESTRIAL ENVIRONMENTS WITHIN A MEGACALDERA IN THE SOUTHERN ALPS (N-ITALY) USING LITHOFACIES ANALYSIS, PALYNOLOGY AND STABLE CARBON ISOTOPES

72. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

73. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

74. Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.

75. The SURVIVE study: Liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer.

76. Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial.

78. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer

79. Vergleich von Trastuzumab-Biosimilar ABP 980 mit Referenz-Trastuzumab bei der neoadjuvanten Therapie von HER2-positivem Brustkrebs – Analyse eines großen universitären Brustkrebszentrums

80. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs

81. Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry

82. Implementation and Evaluation of a Breast Cancer Disease Model Using Real-World Claims Data in Germany from 2010 to 2020

83. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024

85. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

87. Speckle interferometry at SOAR in 2015

88. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

89. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis

91. Contribution to the Domestication and Conservation of the Genetic Diversity of Two Native Multipurpose Species in the Yabotí Biosphere Reserve, Misiones, Argentina

92. Acute relaxation during pregnancy leads to a reduction in maternal electrodermal activity and self-reported stress levels

93. A global metagenomic map of urban microbiomes and antimicrobial resistance

95. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

96. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

100. Densidad y proporción de albura y duramen en nuevos clones de Eucalyptus spp

Catalog

Books, media, physical & digital resources